About: Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis
Creator	Foulongne, Vincent Abely, Michel Caimmi, Davide Chiron, Raphael Cousin, Mathias Molinari, Nicolas Vachier, Isabelle
Source	Medline; PMC
abstract	BACKGROUND: Respiratory viral infections lead to bronchial inflammation in patients with cystic fibrosis, especially during pulmonary exacerbations. The aim of this study was to determine the impact of viral‐associated pulmonary exacerbations in children with cystic fibrosis and failure to improve forced expiratory volume in 1 s (FEV (1)) after an appropriate treatment. METHODS: We lead a pilot study from January 2009 until March 2013. Children with a diagnosis of cystic fibrosis were longitudinally evaluated three times: at baseline (Visit 1), at the diagnosis of pulmonary exacerbation (Visit 2), and after exacerbation treatment (Visit 3). Nasal and bronchial samples were analyzed at each visit with multiplex viral respiratory PCR panel (qualitative detection of 16 viruses). Pulmonary function tests were recorded at each visit, in order to highlight a possible failure to improve them after treatment. Lack of improvement was defined by an increase in FEV (1) less than 5% between Visit 2 and Visit 3. RESULTS: Eighteen children were analyzed in the study. 10 patients failed to improve by more than 5% their FEV (1) between Visit 2 and Visit 3. Rhinovirus infection at Visit 2 or Visit 3 was the only risk factor significantly associated with such a failure (OR, 12; 95% CI, 1·3–111·3), P = 0·03. CONCLUSIONS: Rhinovirus infection seems to play a role in the FEV (1) recovery after pulmonary exacerbation treatment in children with cystic fibrosis. Such an association needs to be confirmed by a large‐scale study because this finding may have important implications for pulmonary exacerbation management.
has issue date	2016-01-29(xsd:dateTime)
bibo:doi	10.1111/irv.12353
bibo:pmid	26493783
has license	cc-by
sha1sum (hex)	71ff6abe3023a4c48fd6e6c54265bce395b88397
schema:url	https://doi.org/10.1111/irv.12353
resource representing a document's title	Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis
has PubMed Central identifier	PMC4746558
has PubMed identifier	26493783
schema:publication	Influenza Other Respir Viruses
resource representing a document's body	covid:71ff6abe3023a4c48fd6e6c54265bce395b88397#body_text
is schema:about of	named entity 'CHILDREN' named entity 'PULMONARY' named entity 'ASSOCIATED' named entity 'IMPROVEMENT' named entity 'RHINOVIRUS' named entity 'CYSTIC FIBROSIS' named entity 'LACK' named entity 'FEV 1' named entity 'FEV' named entity 'morbidity' named entity 'human metapneumovirus' named entity 'FEV' named entity 'antibiotic' named entity 'FEV' named entity 'antibiotic treatment' named entity 'rhinovirus' named entity 'respiratory infection' named entity 'FEV' named entity 'virus' named entity 'pancreatic insufficiency' named entity 'viral infections' named entity 'metapneumovirus' named entity '95% CI' named entity 'consent form' named entity 'body mass index' named entity 'evolution' named entity 'FVC' named entity 'viruses' named entity 'intravenous' named entity 'viruses' named entity 'sputum' named entity 'anaerobic bacteria' named entity 'pancreatic insufficiency' named entity 'non-invasive' named entity 'Virus' named entity 'atopic' named entity 'FEV1' named entity 'infection' named entity 'antibiotic' named entity 'follow-up' named entity 'risk factors' named entity 'Reims' named entity 'pathogens' named entity 'respiratory infections' named entity 'viruses' named entity 'influenza' named entity 'infection' named entity 'rhinovirus' named entity 'FEV' named entity 'host defense' named entity 'multiplex PCR' named entity 'human parainfluenza virus 1' named entity 'OC43' named entity 'Viral' named entity 'respiratory infection' named entity 'human rhinovirus' named entity 'morbidity' named entity 'EudraCT' named entity 'Rhinovirus' named entity 'bronchoscopy' named entity 'infection' named entity 'vaccination' named entity 'recovery period' named entity 'infection' named entity 'viruses' named entity 'diabetes' named entity 'standard deviation' named entity 'FEV' named entity 'antibiotics' named entity 'rhinovirus' named entity 'antibiotic treatment' named entity 'inflammation' named entity 'pathogens' named entity 'Viruses' named entity 'fungi'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software